mdg-annual-report-2013

62 CONSOLIDATED FINANCIAL STATEMENTSCONSOLIDATED INCOME STATEMENTOF MEDIGENE AG FOR THE PERIOD FROM 1 JANUARY TO 31 DECEMBER 2013 AND 2012IN € K NOTE 2013 2012Product sales 4,209 3,384Other operating income 3,383 2,900Total revenue (27) 7,592 6,284Cost of sales (28) -1,735 -1,250Gross profit 5,857 5,034Selling expenses (29) -3,121 -2,271General and administrative expenses (30) -5,152 -5,638Research and development expenses (31) -6,605 -7,399Other expenses (32) 0 -6,166Operating result -9,021 -16,440Interest income (33) 24 55Interest expense (33) -1,577 -1,260Foreign exchange gains 412 689Share of result of an associate (41) -102 -59Income from revaluation of an investment 0 2,220Result from continued operations before tax -10,264 -14,795Taxes (47) -18 -82Result from continued operations -10,282 -14,877Revenue from discontinued operations 0 5,032Selling expenses from discontinued operations 0 -14Result from discontinued operations 0 5,018Net result for the year -10,282 -9,859Basic and diluted earnings per share from continued operations in € 1) (34) -1.07 -1.60Basic and diluted earnings per share from discontinued operations in € 1) (34) 0 0,54Basic and diluted gain/loss per share in € 1) (34) -1.07 -1.061) Following capital reduction in 2013, the earnings per share in the previous year was retroactively multiplied by 4.